Sign in
CompletedNo phase

Vasopressin Use in Septic Shock From Türkiye

Key facts

Who runs it
Karadeniz Technical University
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
146 people enrolled
Started
1 Jan 2024
Ended
15 Jan 2025
Type of study
Observational, 2 groups
Record updated
1 May 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Adult patients (≥18 years old) admitted to the intensive care unit (ICU)
  • Diagnosed with septic shock according to Sepsis-3 criteria
  • Treated with norepinephrine as the initial vasopressor
  • Received norepinephrine alone or norepinephrine with adjunctive vasopressin
  • Admitted between January 1 and December 15, 2024

Who cannot take part

  • Patients who received epinephrine or dopamine prior to or along with vasopressin
  • Patients younger than 18 years
  • Patients with incomplete clinical or hemodynamic data
  • Readmitted ICU patients during the same hospitalization
  • Patients with do-not-resuscitate (DNR) orders at ICU admission

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this observational study is to examine the early hemodynamic effects and clinical outcomes of vasopressin use in patients with septic shock. The study aims to compare adult ICU patients who received norepinephrine alone versus those who received vasopressin in addition to norepinephrine.

Read full original descriptionShow less

The main question it aims to answer is:

Does adding vasopressin to norepinephrine improve blood pressure, lactate levels, and survival in patients with septic shock?

Researchers used retrospective medical records of patients treated between January and December 2024. Data such as blood pressure, heart rate, lactate levels, and mortality were collected and analyzed to assess treatment response and outcomes.

The 2 groups in the trial

  • Norepinephrine Only

    Participants with septic shock who received norepinephrine as the sole vasopressor agent during their ICU stay. No adjunctive vasopressin or other vasopressors were administered. This group served as the reference for comparison of hemodynamic and clinical outcomes.

  • Norepinephrine Plus Vasopressin

    Participants with septic shock who received adjunctive vasopressin in addition to norepinephrine. Vasopressin was initiated during the course of vasodilatory shock based on clinical judgment. The study evaluated hemodynamic response and mortality in this group compared to norepinephrine monotherapy.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Exploring Vasopressin Use in Septic Shock: A Retrospective Cohort Study From Türkiye
Publications
Record updated
1 May 2025